Achieve Life Sciences, Inc. (ACHV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1040 West Georgia Street
Vancouver, BC V6E 4H1
Canada
Phone
14256861500
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
October 12, 1995
| Name | Title | Pay | Year Born |
| Andrew D. Goldberg | CEO, President & Director | 0 | 1982 |
| Mark K. Oki | Chief Financial Officer | 425,244 | 1969 |
| Erik Atkisson | Chief Legal Officer | 521,020 | 1972 |
| Jaime Xinos | Chief Commercial Officer | 585,000 | 1977 |
| Mark L. Rubinstein | Chief Medical Officer | 0 | N/A |
| Craig Donnelly | Chief Operations Officer | 0 | N/A |
| Jerry Wan | Vice President of Finance & Principal Accounting Officer | 0 | 1982 |
| Mark Zappia | Senior Vice President of Commercial | 0 | N/A |
| Nicole Jones | Vice President of Strategic Communications & Stakeholder Relations | 0 | N/A |
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.